

**FINAL PROGRAM**  
*Challenges for Vaccine Development: Medical Needs and Social Implications*  
*April 12-15, 2007*  
*Baden, Austria*

**THURSDAY, APRIL 12, 2007**

- 12.00 – 14.00      *Check-In*  
*Light Lunch / Coffee Buffet*
- 14.00 – 14.20      **Opening Statement by Alexander von Gabain**

**SESSION I – New vaccines in the light of novel and old targets**

*Chair: Franz-Xaver Heinz*

- 14.20 – 14.50      **Allergy vaccines**  
Rudolf Valenta (*Medical University Vienna*)
- 14.50 – 15.20      **Therapeutic vaccination against chronic disease: clinical experience**  
Martin Bachmann (*Cytos Biotechnology*)
- 15.20 – 15.40      *Coffee Break*
- 15.40 – 16.10      **Vaccines against *Staphylococcus aureus***  
John Shiver (*Merck*)
- 16.10 – 16.40      **Therapeutic vaccine against HPV**  
Cornelis Melief (*University of Leiden*)
- 16.40 – 17.00      *Coffee Break*

**KEY NOTE LECTURE**

*Chair: Beatrix Grubeck-Loebenstein*

- 17.00 – 17.30      **Human monoclonal antibodies and analytic vaccinology**  
Antonio Lanzavecchia (*Institute for Research in Biomedicine*)
- 18.30 – 19.00      *Opening of the Poster Session*
- 19.00                *Get Together*

**FRIDAY, APRIL 13, 2007**

- 07.00 – 09.00      *Breakfast*

**SESSION II a – Vaccines in the light of microbial exposure, life stage and immune status**

*Chair: Hubert Blum*

- 09.00 – 09.30      **The PD-1:PD-1 ligand pathway**  
Gordon Freeman (*Harvard Medical School*)
- 09.30 – 10.00      **Role of the cell-mediated immune response in HCV pathogenesis**  
Carlo Ferrari (*Unit of Infectious Diseases and Hepatology – Laboratory of Viral Immunopathology – Azienda Ospedaliero-Universitaria die Parma*)
- 10.00 – 10.30      **Immunity and aging**  
Beatrix Grubeck-Loebenstein (*Inst. f. Biomedical Aging Research of the Austrian Academy of Sciences, Innsbruck*)

**FINAL PROGRAM**  
*Challenges for Vaccine Development: Medical Needs and Social Implications*  
*April 12-15, 2007*  
*Baden, Austria*

- 10.30 – 11.00      *Coffee Break*
- 11.00 – 11.30      The challenge of early life vaccination  
Paul-Henri Lambert (*University of Geneva*)
- 11.30 – 12.00      Adjuvant Activity of Type I Interferon  
Michael Tovey (*Institute Andre Lwoff, Villejuif*)
- 12.00 – 13.30      *Lunch Break*

**SESSION II b – Vaccines in the light of microbial exposure, life stage and immune status**

*Chair: Alexander von Gabain*

- 13.30 – 14.00      A novel TB-Subunit Vaccine  
Tom Ottenhof (*University of Leiden*)
- 14.00 – 14.30      The Population-Level Impact of Routine Infant Immunization with Pneumococcal  
Conjugate Vaccine in the U.S.  
Art Reingold (*Berkeley School of Public Health*)
- 14.30 – 15.00      Vaccines in the field  
Regina Rabinovich (*Bill & Melinda Gates Foundation*)
- 19.30                *Austrian Evening*

**SATURDAY, APRIL 14 2007**

- 07.00 – 08.30      *Breakfast*

**SESSION III – Novel vaccines in the light of markets and social implications**

*Chair: Regina Rabinovich*

- 08:30 – 09:00      Primary Prevention of Cervical Cancer with GARDASIL® (Quadrivalent Human  
Papillomavirus [HPV] Vaccine)  
Mark Feinberg (*Merck*)
- 09:00 – 09:30      Case Study: Rotarix™, a human attenuated oral rotavirus vaccine for global use  
Béatrice De Vos (*GSK*)
- 09.30 – 10.00      *Coffee Break*
- 10.00 – 10.30      Development of a Cell-Culture Derived H5N1 Pandemic Influenza Vaccine  
Otfried Kistner (*Baxter*)
- 10.30 – 11.00      Japanese Encephalitis: A global vaccine approach for a global immunization need  
Erich Tauber (*Intercell*)
- 11.00 – 12.30      *Lunch Break*

**FINAL PROGRAM**  
*Challenges for Vaccine Development: Medical Needs and Social Implications*  
*April 12-15, 2007*  
*Baden, Austria*

SESSION IV – Novel vaccine strategies in the light of advancing technologies

*Chair: Thomas Decker*

- 12.30 – 13.00      The induction of immunity or tolerance – A challenge for mucosal vaccine development  
Jan Holmgren (*Göteborg University*)
- 13.00 – 13.30      Toll like receptor (TLR) agonists and ZOT-derived peptides as vaccine adjuvants  
Sefik S. Alkan (*3M and ALBA Therapeutics*)
- 13.30 – 14.00      Monoclonal antibodies, a new paradigm in infectious diseases  
Eszter Nagy (*Intercell*)
- 14.00 – 14.30      *Coffee Break*
- 14.30 – 15.00      L15 as a vaccine adjuvant to induce long-lived, high avidity memory CD8 T-cells, even in CD4-deficient hosts  
Jay A. Berzofsky (*NCI, Bethesda*)
- 15.00 – 15.30      M2e-based Universal Influenza A Vaccine  
A. Walter Fiers (*University of Ghent*)
- 15.30 – 16.00      It's Prime Time for Clinical Trials of Plasmid DNA Vaccine  
Ron Moss (*Vical*)
- 16.00 – 16.30      *Coffee Break*

ROUND TABLE

The future of vaccines in the light of commercial, social and disease challenges

*Chair: Gerd Zettlmeissl*

- 16.30 – 18.30      Jeffrey Almond (*Vice President, Sanofi Pasteur*)  
Alexander von Gabain (*CSO and Founder, Intercell*)  
Michel Gréco (*Independent Vaccine Expert*)  
John Hodgson (*Nature Biotechnology*)  
Jacques-François Martin (*Parteurop Développement*)  
Regina Rabinovich (*Director of the Infectious Diseases program, Gates Foundation*)  
Ray Spier (*Vaccines*)  
Mike Ward (*Biocentury*)
- 19.30                      *Gala Dinner*